Reshaping Risk/Reward in Biotech VC
As returns from internet start-ups continue to reshape venture capital, the risk/reward ratios for biotech companies become less attractive for VC's. Since the biotechnology industry plays a direct role in improving health care, perhaps what's needed are investment incentives provided by public policy.
You may also be interested in...
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.
Company seeks to avoid Medicaid “best price” implications by administering the program through an insurance policy with AIG, which is handling claims for refunds and processing payments.